CALGB/SWOG 80405: Genome-Wide Association Study of Patients with Advanced or Metastatic Colorectal Cancer Treated with First-Line Chemotherapy Combined with Cetuximab and/or Bevacizumab

Request Access

Anthropometry (1)

BMI - Body mass index (phv00532550.v1.p1)

Biomarkers (22)

bm_Ang.2 - Circulating protein level for angiopoietin-2 at baseline (phv00532587.v1.p1)
bm_BMP.9 - Circulating protein level for BMP-9 at baseline (phv00532597.v1.p1)
bm_CD73 - Circulating protein level for CD73 at baseline (phv00532598.v1.p1)
bm_HER.3 - Circulating protein level for HER-3 at baseline (phv00532599.v1.p1)
bm_HGF - Circulating protein level for HGF at baseline (phv00532591.v1.p1)
bm_ICAM.1 - Circulating protein level for ICAM-1 at baseline (phv00532588.v1.p1)
bm_IL.6 - Circulating protein level for IL-6 at baseline (phv00532583.v1.p1)
bm_PDGF.AA - Circulating protein level for PDGF-AA at baseline (phv00532582.v1.p1)
bm_PDGF.BB - Circulating protein level for PDGF-BB at baseline (phv00532592.v1.p1)
bm_PlGF - Circulating protein level for PlGF at baseline (phv00532594.v1.p1)
bm_SDF.1 - Circulating protein level for SDF-1 at baseline (phv00532596.v1.p1)
bm_TGF.b2 - Circulating protein level for TGF-b2 at baseline (phv00532579.v1.p1)
bm_TGFb.R3 - Circulating protein level for TGFb-R3 at baseline (phv00532600.v1.p1)
bm_TGFb1 - Circulating protein level for TGF-b1 at baseline (phv00532578.v1.p1)
bm_TIMP.1 - Circulating protein level for TIMP-1 at baseline (phv00532589.v1.p1)
bm_TSP2 - Circulating protein level for TSP-2 at baseline (phv00532585.v1.p1)
bm_VCAM.1 - Circulating protein level for VCAM-1 at baseline (phv00532590.v1.p1)
bm_VEGF.A - Circulating protein level for VEGF-A at baseline (phv00532593.v1.p1)
bm_VEGF.D - Circulating protein level for VEGF-D at baseline (phv00532580.v1.p1)
bm_VEGF.R1 - Circulating protein level for VEGF-R1 at baseline (phv00532584.v1.p1)
bm_VEGF.R2 - Circulating protein level for VEGF-R2 at baseline (phv00532595.v1.p1)
bm_VEGF.R3 - Circulating protein level for VEGF-R3 at baseline (phv00532586.v1.p1)

Demographics (5)

age - Age (phv00532554.v1.p1)
fu_time - Overall survival time (phv00532569.v1.p1)
pf_time - Progression-free survival time (phv00532570.v1.p1)
SEX - Genetically estimated sex (via PLINK) (phv00532546.v1.p1)
SEX_ID - Self-reported gender (phv00532555.v1.p1)

Disease Events (3)

dead - Overall survival status (phv00532568.v1.p1)
familyhx - Family history of colon cancer (phv00532553.v1.p1)
pf_stat - Progression-free survival status (phv00532571.v1.p1)

Medications (1)

STATIN - Statin use (phv00532551.v1.p1)

Race and Ethnicity (2)

ETHNIC_ID - Self-reported ethnicity (phv00532803.v1.p1)
RACE_ID - Self-reported race (phv00532556.v1.p1)

Substance Use (1)

SMOKE - Smoking status (phv00532552.v1.p1)

Other (31)

ABD - Metastatic site (intra-abdominal) (phv00532573.v1.p1)
ANALYTE_TYPE - Analyte type (phv00532607.v1.p1)
AXIN1paper - AXIN1 analysis cohort i.e. included in the 80405 manuscript published in Clinical Cancer Research (Innocenti, Federico, et al. "Genomic analysis of germline variation associated with survival of patients with colorectal cancer treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance)." Clinical Cancer Research 27.1 (2021): 267-275.) (phv00532601.v1.p1)
bm_OPN - Circulating protein level for OPN at baseline (phv00532581.v1.p1)
BODY_SITE - Body site where sample was collected (phv00532606.v1.p1)
BONE - Metastatic site (bone) (phv00532575.v1.p1)
BRAF2 - BRAF V600E mutation status (phv00532558.v1.p1)
CMS - Consensus molecular subtype (phv00532560.v1.p1)
CNS - Metastatic site (CNS/brain) (phv00532576.v1.p1)
CONSENT - Consent group as determined by DAC (phv00532545.v1.p1)
genetic_european - Subject identified as genetic European in AXIN1 manuscript (AXIN1paper) (phv00532604.v1.p1)
IS_TUMOR - Tumor status (phv00532608.v1.p1)
KRASCONFIRM - KRAS determination (phv00532562.v1.p1)
KRASpaper - KRAS analysis cohort (manuscript in preparation) (phv00532603.v1.p1)
LIVER - Metastatic site (liver) (phv00532574.v1.p1)
LUNG - Metastatic site (lung) (phv00532572.v1.p1)
MSI2 - Microsatellite instability status (phv00532559.v1.p1)
OTHERSITE1 - Metastatic site (other) (phv00532577.v1.p1)
PERFORMANCE_ID - Performance score (phv00532567.v1.p1)
pQTLpaper - PQTL analysis cohort i.e. included in 80405 manuscript that this submission is associated with (phv00532602.v1.p1)
pr_adj - Prior adjuvant chemotherapy (phv00532565.v1.p1)
pr_rad - Prior pelvic radiation therapy (phv00532566.v1.p1)
primary - Primary analysis cohort i.e. included in the 80405 primary endpoint manuscript published in JAMA (Venook AP, et al. JAMA. 2017;317(23):2392-2401.) (phv00532563.v1.p1)
prot_chemo - Planned protocol chemotherapy (phv00532564.v1.p1)
SAMPLE_ID - Sample ID (phv00532605.v1.p1)
SAMPLE_ID - Sample ID (phv00532548.v1.p1)
side - Tumor location (sidedness) (phv00532557.v1.p1)
SUBJECT_ID - Subject ID (phv00532549.v1.p1)
SUBJECT_ID - Subject ID (phv00532544.v1.p1)
SUBJECT_ID - Subject ID (phv00532547.v1.p1)
TREAT_ASSIGNED - Treatment arm (phv00532561.v1.p1)